Brokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Target Price at $5.17

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $5.17.

SGMO has been the topic of a number of research reports. Barclays lifted their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Truist Financial cut their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. StockNews.com cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Wells Fargo & Company cut their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 31st. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Monday, January 27th.

Institutional Trading of Sangamo Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. E Fund Management Co. Ltd. acquired a new stake in Sangamo Therapeutics in the fourth quarter valued at $25,000. JPMorgan Chase & Co. grew its holdings in Sangamo Therapeutics by 679.5% during the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 21,793 shares during the period. PNC Financial Services Group Inc. increased its position in Sangamo Therapeutics by 2,319.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in Sangamo Therapeutics in the fourth quarter valued at approximately $28,000. Finally, Shelton Wealth Management LLC acquired a new stake in shares of Sangamo Therapeutics in the fourth quarter valued at approximately $29,000. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Price Performance

NASDAQ:SGMO opened at $1.07 on Wednesday. The business’s 50-day simple moving average is $1.45 and its 200-day simple moving average is $1.40. Sangamo Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.18. The stock has a market capitalization of $223.26 million, a PE ratio of -1.43 and a beta of 1.30.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.